Immutep (ASX: IMM) has outlined a more focused development strategy for eftilagimod alfa (efti), concentrating future registration-directed work on head and nec...
Market Samachar is a news aggregator. This article was originally published by smallcaps.com.au. Tap the button above to read the full story on their site.